Pharma major Dr Reddy's faced a challenging first quarter, impacted by weak US sales due to heightened competition and pricing pressures. Analysts expect a 4% decline in net profit year-on-year despite an 8% increase in revenues. Higher Revlimid sales might offset the subdued US performance.
